Population pharmacokinetic models of tacrolimus in paediatric solid organ transplant recipients: A systematic review
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.15909 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Kanyaporn Khamlek und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Kidney Transplantation, Organ Transplantation. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 65 Literaturangaben.
Abstract (Originalsprache)
Aims
This study aimed to provide up‐to‐date information on paediatric population pharmacokinetic models of tacrolimus and to identify factors influencing tacrolimus pharmacokinetic variability.
Methods
Systematic searches in the Web of Science, PubMed, Scopus, Science Direct, Cochrane, EMBASE databases and reference lists of articles were conducted from inception to March 2023. All population pharmacokinetic studies of tacrolimus using nonlinear mixed‐effect modelling in paediatric solid organ transplant patients were included.
Results
Of the 21 studies reviewed, 62% developed from liver transplant recipients and 33% from kidney transplant recipients. Most studies used a 1‐compartment model to describe tacrolimus pharmacokinetics. Body weight was a significant predictor for tacrolimus volume of distribution (Vd/F). The estimated Vd/F for 1‐compartment models ranged from 20 to 1890 L, whereas the peripheral volume of distribution (Vp/F) for 2‐compartment models was between 290 and 1520 L. Body weight, days post‐transplant, CYP3A5 genotype or haematocrit were frequently reported as significant predictors of tacrolimus clearance. The estimated apparent clearance values range between 0.12 and 2.18 L/h/kg, with inter‐individual variability from 13.5 to 110.0%. Only 29% of the studies assessed the generalizability of the models with external validation.
Conclusion
This review highlights the potential factors, modelling approaches and validation methods that impact tacrolimus pharmacokinetics in a paediatric population. The clinician could predict tacrolimus clearance based on body weight, CYP3A5 genotype, days post‐transplant or haematocrit. Further research is required to determine the relationship between pharmacogenetics and tacrolimus pharmacodynamics in paediatric patients and confirm the applicability of nonlinear kinetics in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
ORCID-Profile: Kanyaporn Khamlek, Virunya Komenkul, Tatta Sriboonruang, Thitima Wattanavijitkul
Zitieren
APA
Khamlek, K., Komenkul, V., Sriboonruang, T., & Wattanavijitkul, T. (2024). Population pharmacokinetic models of tacrolimus in paediatric solid organ transplant recipients: A systematic review. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15909
Vancouver
Khamlek K, Komenkul V, Sriboonruang T, Wattanavijitkul T. Population pharmacokinetic models of tacrolimus in paediatric solid organ transplant recipients: A systematic review. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.15909
BibTeX
@article{Khamlek2024,
author = {Khamlek, Kanyaporn and Komenkul, Virunya and Sriboonruang, Tatta and Wattanavijitkul, Thitima},
title = {Population pharmacokinetic models of tacrolimus in paediatric solid organ transplant recipients: A systematic review},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.15909}
}
EUVIMED